arrow_back Back Filing freshness 20-F Q4 FY2025 SEC EDGAR

NewcelX Ltd.

NCEL
$2.77 ▲ +0.27 (+10.58%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
9 Visible periods
7 Metrics
Peer-ranked Benchmarks
Price Chart
14
Health
Poor
Bearish
auto_awesome

Analytical Summary

NewcelX Ltd. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC —
FCF / Share —
Trailing P/E —
Price / Book 1.8x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
7
Financial Health ↑
12
Cash Quality ↓
33

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 9 years · 9 quarters